Cocrystal Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the
“Company”), a clinical-stage biotechnology company discovering and
developing novel antiviral therapeutics, announces management will
present at the H.C. Wainwright Virtual BioConnect Conference being
held January 11-14, 2021. The presentation can be accessed on the
IR Calendar section of the Cocrystal website beginning on January
11, 2021 at 6:00 a.m. Eastern time.
“We are pleased with our progress in 2020 in
advancing our pipeline of novel antiviral compounds,” said Gary
Wilcox, Ph.D., Chairman and Chief Executive Officer of Cocrystal.
“We look forward to presenting at this conference and introducing
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage
biotechnology company discovering and developing novel antiviral
therapeutics that target the replication process of influenza
viruses, hepatitis C viruses, coronaviruses and noroviruses.
Cocrystal employs unique structure-based technologies and Nobel
Prize-winning expertise to create first- and best-in-class
antiviral drugs. For further information about Cocrystal, please
Investor Contact:LHA Investor RelationsJody
# # #